Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind 12-week study of dexlansoprazole delayed-release capsules in pediatric symptomatic nonerosive GERD
2014-004506-15Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of days without hurting or burning in the stomach, chest, or throat over 12 weeks. Started Oct 2015; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2014-004506-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004506-15.